Kwok Yan Ling, Wang Ran, Tang Hiu To, Chen Siyu, Yeung Albert, Bian Zhaoxiang, Yu Danny J
Vincent V.C. Woo Chinese Medicine Clinical Research Institute, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.
School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.
Integr Med Res. 2025 Dec;14(4):101208. doi: 10.1016/j.imr.2025.101208. Epub 2025 Jul 29.
Over 20 % of adults with insomnia disorder also experience chronic pain, termed insomnia disorder comorbid with chronic pain (ICCP), increasing risks for physical and mental diseases. Current treatments like cognitive behavioral therapy for insomnia show inconsistent pain relief, and non-opioid analgesics may exacerbate insomnia, underscoring the need for alternative approaches. Chinese herbal medicine (CHM) and acupuncture, guided by traditional Chinese medicine, may offer transdiagnostic benefits for ICCP, but a comprehensive review is lacking. This scoping review evaluates their therapeutic effects and mechanisms for ICCP.
PubMed, Wanfang, ClinicalTrials.gov and Google Scholar were searched up to December 31, 2024, for randomized controlled trials (RCTs) involving adults (≥18 years) with Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition-defined insomnia and the International Association for the Study of Pain-defined chronic pain, treated with CHM or acupuncture. Effect sizes (modified Cohen's d) assessed efficacy of interventions, and the Cochrane Risk of Bias 2 tool evaluated the risk of bias.
Six RCTs (487 participants) were included. CHM (modified Guipi decoction) showed medium to large effects for insomnia ( = 0.70-1.17) and pain ( = 0.67-1.42) versus diazepam/estazolam. Acupuncture had medium to large effects for insomnia ( = 0.64-0.99) and pain ( = 0.80-1.33) compared to treatment as usual. Combined CHM (Da Huoluo capsules) and acupuncture showed medium effects ( = 0.72 for insomnia; = 0.57 for pain) versus multi-medications/traction. Most studies (83.33 %) had high risk of bias.
CHM and acupuncture show promise for ICCP management, but high risk of bias warrants cautious interpretation and further high-quality RCTs.
超过20%的失眠症成年患者同时患有慢性疼痛,称为失眠症合并慢性疼痛(ICCP),这增加了身心疾病的风险。目前的治疗方法,如失眠认知行为疗法,在缓解疼痛方面效果不一,非阿片类镇痛药可能会加重失眠,这凸显了需要替代方法。以传统中医为指导的中药(CHM)和针灸可能为ICCP提供跨诊断益处,但缺乏全面的综述。本范围综述评估了它们对ICCP的治疗效果和机制。
截至2024年12月31日,在PubMed、万方、ClinicalTrials.gov和谷歌学术上搜索涉及患有《精神疾病诊断与统计手册》第五版定义的失眠症和国际疼痛研究协会定义的慢性疼痛的成年人(≥18岁),接受中药或针灸治疗的随机对照试验(RCT)。效应量(修正的科恩d值)评估干预措施的疗效,Cochrane偏倚风险2工具评估偏倚风险。
纳入了6项RCT(487名参与者)。与地西泮/艾司唑仑相比,中药(改良归脾汤)对失眠(=0.70-1.17)和疼痛(=0.67-1.42)显示出中等到较大的效果。与常规治疗相比,针灸对失眠(=0.64-0.99)和疼痛(=0.80-1.33)显示出中等到较大的效果。联合中药(大活络胶囊)和针灸与多种药物/牵引相比显示出中等效果(失眠=0.72;疼痛=0.57)。大多数研究(83.33%)存在高偏倚风险。
中药和针灸在ICCP管理方面显示出前景,但高偏倚风险值得谨慎解读,并需要进一步开展高质量的RCT。